ProPhase Labs, Inc. (PRPH): Operating Cash Flow
-$8.34M
Year ended 2025-12-31
-$5.54M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$8.34M | n/m | 2026-06-01, From 2025-01-01 |
| 2024-12-31 | -$17.54M | n/m | 2026-06-01, From 2024-01-01 |
| 2023-12-31 | -$11.89M | n/c | 2025-04-01, From 2023-01-01 |
| 2022-12-31 | $28.55M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$13.62M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$2.59M | n/c | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$841.0K | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$2.12M | n/m | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | -$2.84M | n/m | 2019-03-26, From 2017-01-01 |
| 2016-12-31 | -$472.0K | n/m | 2018-08-20, From 2016-01-01 |
| 2015-12-31 | -$3.50M | n/m | 2018-08-20, From 2015-01-01 |
| 2014-12-31 | -$3.22M | n/m | 2017-02-24, From 2014-01-01 |
| 2013-12-31 | $1.14M | n/m | 2016-03-29, From 2013-01-01 |
| 2012-12-31 | -$5.73M | n/m | 2013-03-28, From 2012-01-01 |
| 2011-12-31 | -$2.11M | n/m | 2013-03-28, From 2011-01-01 |
| 2010-12-31 | -$3.55M | n/m | 2013-03-28, From 2010-01-01 |
| 2009-12-31 | $445.0K | n/a | 2012-03-07, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$8.34M | n/m |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $148.3K | n/m |
| CervoMed Inc. (CRVO) | 2025-12-31 | -$23.45M | n/m |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | -$7.81M | n/m |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | -$12.01M | n/m |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | -$29.55M | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $2.45M | +109.7% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | -$2.29M | n/m |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | -$78.56M | n/m |
Compare PRPH, CPHI, CRVO, ENSC side by side · Screen every company in Pharmaceutical Preparations ↗